Truist Financial analyst Nicole Germino assigned a Buy rating to the stock today. The company’s shares closed yesterday at $13.00.

Perspective Therapeutics (CATX) stock drops 17% after mixed results from a Phase 1/2 trial for its radiopharmaceutical VMT01 ...

Wedbush has recently initiated Perspective Therapeutics Inc (CATX) stock to Outperform rating, as announced on October 1, 2024, according to Finviz. Earlier, on September 25, 2024 ...

We recently published a list of 10 Small Cap Stocks with High Potential. In this article, we are going to take a look at ...

In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics (CATX – Research Report), ...

Shares of Perspective Therapeutics are down after results from a study of the company's treatment for melanoma showed lower doses were more effective, and higher-than-expected levels of radiation were ...

Perspective Therapeutics is down 13% at last check Friday. The downtrend comes as drug study results are presented to medical ...

On Monday, Oppenheimer reaffirmed its Outperform rating on Perspective Therapeutics Inc (NYSE:CATX), maintaining a price target of $22.00. The affirmation follows an announcement made by the ...

SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced ...

In this article, we are going to take a look at where Perspective Therapeutics, Inc. (NYSE:CATX) stands against other small cap stocks with high potential. As we transition from a tumultuous ...

On Monday, Oppenheimer reaffirmed its Outperform rating on Perspective Therapeutics Inc (NYSE:CATX), maintaining a price target of $22.00. The affirmation follows an announcement made by the company ...